Noxopharm Ltd has released a press release.
March Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- Veyonda Showing Potential to Prevent Cytokine Storm
- Noxopharm Files Septic Shock Treatment Patent for Veyonda®
- Veyonda Patent Lodged for Major Septic Shock Opportunity
- Noxopharm IONIC Immuno-Oncology Trial Commences
- NOXCOVID Trial Advances to Final Stage
Later from Noxopharm
- Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
- Publications Positive Review of Veyonda in Chemotherapy
- Veyonda FDA Approved Trial to Commence
- Veyonda to Begin First-Line Sarcoma Treatment Testing
- New Independent Trial Data Supports Potential of Veyonda
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm